Strengths and limitations of this study 77  This protocol was registered with PROSPERO and PRISMA-P guidelines were followed.
78
 Two reviewers will conduct screening and data extraction to reduce bias.
79
 Heterogeneity of results will be assessed.
80
 Grey literature will be excluded. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The search strategy will include key-terms and database specific terminology; for 177 example, Medical Subject Headings (MeSH). We will be using databases including: Medline (1980 ( -present), Embase (1980 , CINAHL (1980-present) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Descriptive data will be summarized using a narrative style. A meta-analysis will be 226 conducted if heterogeneity is not a major concern. The I 2 statistic will be used to assess 227 heterogeneity where 25%, 50%, and 75% will represent low, moderate, and high heterogeneity, 228 respectively. 17 Additionally, the Chi-Square test for heterogeneity will also be used. P-value 229 <0.1 will indicate significant heterogeneity. If heterogeneity is found, P-values less than or equal 230 to 0.05 will be considered statistically significant. A Forest plot will be used to graphically assess 231 heterogeneity. The RevMan software will be used to generate the Forest Plot. Measures of 232 association reported by studies to be included in the meta-analysis will be summarized using 233 the random effects model for meta-analysis. If heterogeneity is found, sensitivity and subgroup 234 analyses will be performed. The R Project for Statistical Computing will be used to conduct 235 analyses.
178
236 .
237
Quality Assessment #2 "sexually transmitted infection" OR "sexually transmitted infections" OR STI OR STIs OR "sexually transmitted disease" OR "Sexually transmitted diseases" OR STD OR STDs OR "venereal disease" OR "venereal diseases" OR chlamydia OR syphilis OR "herpes simplex virus type 2" OR HSV2 OR gonorrhea OR trichomoniasis OR "trichomonas vaginalis"
#3 "Human Immunodeficiency Virus" OR HIV OR "human immunodeficiency virus infection" OR "acquired immunedeficiency syndrome" OR AIDS OR "acquired immuno-deficiency syndrome" OR "human immunedeficiency virus"
OR "human immune-deficiency virus" 
PRISMA-P 2015 Checklist
This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 
STUDY RECORDS
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 205-207
Selection process 11b State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)
183-189
Data collection process 11c Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
193-202

Data items 12
List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications
141-143
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale
Risk of bias in individual studies 14
Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis The search strategy will include key-terms and database specific terminology; for 181 example, Medical Subject Headings (MeSH). We will be using databases including: Medline (1980 ( -present), Embase (1980 , CINAHL (1980-present) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9   190 are included in Table 1 We have included the overall search strategy in Table 2 . Boolean 191 operators, AND/OR will be included in the search strategy for the key terms and the MeSH 192 words. The detailed strategy for MEDLINE is included in Table 3 . No language restrictions will 193 be applied. The search strategy will be pilot tested and finalized.
182
195
All three independent reviewers (SK, MC and FS) will meet to identify the screening and 196 data extraction process and conduct the literature search of all databases. The results of each 197 database specific search strategy will be downloaded from the respective databases. We will 198 then import the combined search results into Covidence, a reference software for full screen 199 review and citations screening. 16 Duplicates will be checked for and removed. An automated 200 check for duplicate titles and year of publication will be applied. The authors will manually check 201 each possible duplicate before removal to decrease error. The updated library will then be 202 saved. Using Covidence, two independent reviewers (from among SK, MC and FS) will screen 203 the titles and abstracts based on the eligibility criteria identified to determine which studies 204 should be included for full text screening. If any disagreement occurs, two authors will discuss 205 and resolve any issues. If no consensus is reached, the third author will arbitrate. Next, eligible 206 full text articles will be screened by two independent reviewers (from among SK, MC and FS) for 207 inclusion in the data extraction process. If any disagreement occurs, two authors will discuss 208 and resolve any issues. If no consensus is reached, the third author will arbitrate. Reasons for 209 exclusion will be referenced for each article at each stage. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 the association between treatment intervention and the acquisition of STIs.
222
The two reviewers will meet to resolve and discuss any disagreements. However, if 223 disagreements persist, the third reviewer will arbitrate. For any missing information, the 224 reviewers will contact the corresponding authors to request any updates on the missing items.
225
Authors will be contacted a maximum of three times via email and/or phone. Email will be the 226 first form of contact. If unsuccessful, three attempts will then be made to call the authors.
228
Data Management
229
Covidence will be used for title and abstract screening and full-text screening. After each 230 round of screening a backup database will be saved. Reasons for exclusion of articles at each 231 stage will be documented in Covidence.
233
Data Synthesis 234 All data will be stratified by intervention type. TasP and PrEP populations will not be 235 mixed. Findings for TasP and PrEP populations will be presented independently. Descriptive 236 data will be summarized using a narrative style. A meta-analysis will be conducted if 237 heterogeneity is not a major concern. The I 2 statistic will be used to assess heterogeneity where 238 25%, 50%, and 75% will represent low, moderate, and high heterogeneity, respectively. 17 239 Additionally, the Chi-Square test for heterogeneity will also be used. P-value <0.1 will indicate 240 significant heterogeneity. If heterogeneity is found, P-values less than or equal to 0.05 will be 241 considered statistically significant. A Forest plot will be used to graphically assess 
277
There are no formal ethics approvals needed for this review because we will only use 278 data that is publicly available. The findings of this review will be published in a peer-reviewed 279 journal. These findings will also be presented at relevant conferences. The PRISMA-P 280 guidelines were used to report this protocol. Findings, as well as any amendments made, will 281 also be reported using the PRISMA guidelines. 
PRISMA-P 2015 Checklist
This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
112-115
METHODS
Eligibility criteria 8
Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review
128-158
Information sources 9 Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage
162-165
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 330
STUDY RECORDS
183-189
193-202
Data items 12
141-143
Risk of bias in individual studies 14
Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 233-241
DATA
15a Describe criteria under which study data will be quantitatively synthesized 210-211 15b
If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I 2 , Kendall's tau)
211-218 15c
Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, metaregression)
218-220
Synthesis 15d If quantitative synthesis is not appropriate, describe the type of summary planned 210 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 
